Proteome-wide and network pharmacology integration identifies sunitinib as a potential therapeutic for type 2 diabetes targets
This study identifies novel T2D therapeutic targets and highlights sunitinib as a promising candidate. Future work should validate these findings and assess sunitinib's efficacy in clinical trials.
Authors
- Yuanyuan Kong (ORCID: https://orcid.org/0000-0002-2586-1443)
- Hong Zhu (ORCID: https://orcid.org/0000-0002-9489-1531)
- Huixin Tong
- Hao Yu (ORCID: https://orcid.org/0009-0001-1183-1446)
- Liang Shi
Institutions
- General Hospital of Shenyang Military Region (CN)
Publication Details
- Journal
- Therapeutic Advances in Endocrinology and Metabolism
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/20420188251376325
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00